南昌治疗神经衰弱的医院那个好南昌敏感多疑症那个医院治,南昌有治精神分裂医院吗,南昌哪里神经官能症医院好,南昌治疗焦虑去哪家中医院,南昌中医治疗焦虑症好,南昌忧郁那个医院好,南昌治疗抑郁症的办法哪种效果好

WASHINGTON (AP) — Federal health officials warned parents Wednesday about the dangers of teething remedies that contain a popular numbing ingredient and asked manufacturers to stop selling their products intended for babies and toddlers.The Food and Drug Administration said that various gels and creams containing the drug benzocaine can cause rare but deadly side effects in children, especially those 2 years and younger.The agency has been warning about the products for a decade but said reports of illnesses and deaths have continued. Now, it wants teething products off the market, noting there is little evidence they actually work."We urge parents, caregivers and retailers who sell them to heed our warnings and not use over-the-counter products containing benzocaine for teething pain," said FDA Commissioner Scott Gottlieb, in a statement.One major manufacturer, Church and Dwight Co. Inc., said Wednesday it would discontinue its four Orajel teething brands, including Baby Orajel and Orajel Medicated Teething Swabs.The FDA said it will take legal action against other companies that don't voluntarily comply as soon as possible.Benzocaine is also used in popular over-the-counter products for toothaches and cold sores in adults, including Orajel and Anbesol and generic drugstore brands. Products for adults can remain on the market but the FDA wants companies to add new warnings. Church and Dwight will continue to sell its other Orajel products, the company said in a statement.Benzocaine can cause a rare blood condition linked to potentially deadly breathing problems. The pain-relieving ingredient can interfere with an oxygen-carrying protein in the blood. Symptoms include shortness of breath, headache and rapid heart rate.The American Academy of Pediatrics does not recommend teething creams because they usually wash out of the baby's mouth within minutes. Instead, the group recommends giving babies teething rings or simply massaging their gums to relieve pain.The FDA issued warnings about the teething products in 2006, 2011 and 2014, but it did not call for their removal from the market. Officials reviewed 119 cases of the blood disorder linked to benzocaine between 2009 and 2017, including four deaths, according to the FDA.Wednesday's action comes more than four years after the consumer advocacy group Public Citizen petitioned the FDA to stop sales of teething products. The agency faced a deadline next week after Public Citizen sued the FDA to force a response to the petition. 2526

WASHINGTON — In an official update on his health status since contracting COVID-19, President Donald Trump told his personal physician “I feel great” Wednesday morning.In a statement shared on Twitter, Dr. Sean Conley also said the president’s vital signs remain “stable and in the normal range.” He added that Trump has not had a fever in more than four days and has not needed “supplemental oxygen since initial hospitalization.”Meanwhile, the president is remaining inside the White House as he recovers and has no public events scheduled Wednesday. Aides are being told to take extensive precautions to prevent themselves from catching the coronavirus. 664

WASHINGTON — A House Republican aide says Rep. Louie Gohmert has tested positive for the coronavirus.The 66-year-old Texas Republican was screened for the virus at the White House on Wednesday morning.Gohmert had gone to the White House because he was planning to fly to Texas with President Donald Trump aboard Air Force One. Gohmert had to cancel his trip and is planning to isolate.The aide wasn't authorized to publicly discuss Gohmert’s test result and spoke on condition of anonymity.Gohmert is one of the House’s most conservative and outspoken members.Gohmert is often seen without wearing a mask on Capitol Hill.On Monday, President Donald Trump's national security adviser, Robert O'Brien, tested positive for COVID-19, the highest-ranking member of the Trump administration to contract the virus. 815

Vigorous pyrocumulus growth associated with the #PineGulchFire (seen here via GOES 16) has produced frequent lightning flashes (blue dots in the image) the last few hours. Thunder, lightning and falling ash have all been observed here at the office. Absolutely wild! ??? #COwx pic.twitter.com/F7qIzaoNi7— NWS Grand Junction (@NWSGJT) August 19, 2020 357

Walgreens has finally figured out a way to buy Rite Aid -- or about half of it, at least.The pharmacy giant said Tuesday that federal regulators have accepted its .4 billion deal to buy 1,932 Rite Aid stores. That will leave Rite Aid with about 2,600 stores once the deal is finished.The purchase marks the end of a two-years-long fight for Walgreens, which initially tried to buy Rite Aid outright for billion in October 2015.The merger agreement faced intense scrutiny from the start, since it would have left the United States with just two major pharmacy chains: Walgreens and CVS.The agreement was reworked several times over the past few years as Walgreens scaled back the number of stores it intended to purchase. In June, the company tried for a .2 billion deal that would have handed it 2,186 Rite Aid stores.Walgreens recently revised its deal again, said company spokesman Michael Polzin. Polzin said that the waiting period for review by the Federal Trade Commission expired last night at midnight, effectively giving Walgreens the regulatory clearance it needs to move forward.The Rite Aid pharmacies that Walgreens plans to buy will eventually be rebranded as Walgreens stores. But it won't happen all at once.Polzin said the company will begin buying Rite Aids in October, adding that it expects to finish doing so in the spring of 2018.Rite Aid stock was down nearly 7% in premarket trading Tuesday morning -- a change from Monday, when it rose as investors hoped for a better deal.Walgreens stock, meanwhile, was up 2% Tuesday before open. 1572